How Psychedelics Rewire Brain: Neuroplasticity Explained Robin Carhart Psychedelic Podcast

In this episode of the Psychedelic Medicine Podcast, Robin Carhart-Harris, PhD explores the science of psychedelics and neuroplasticity and how compounds like psilocybin, ketamine, and MDMA may help rewire the brain in depression, anxiety, and substance use disorders. How Psychedelics Rewire the Brain: Neuroplasticity Explained by Robin Carhart-Harris, PhD | Psychedelic Medicine Podcast Dr. Carhart-Harris is the Ralph Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco. He previously founded the Centre for Psychedelic Research at Imperial College London, helping lead groundbreaking research into psychedelic therapy. What You’ll Learn in This Episode: • How psychedelics enhance neuroplasticity and brain flexibility • The link between neuroplasticity and depression • Differences between ketamine, MDMA, and serotonergic psychedelics • The entropic brain hypothesis explained • Psychedelics and the default mode network (DMN) • Brain network modularity and mental health • Why combining ketamine with psychotherapy improves outcomes • The latest research frontiers in psychedelic science Dr. Carhart-Harris explains how chronic stress can atrophy the brain, reducing neural flexibility and contributing to mood disorders. He clarifies the difference between neuroplasticity (the brain’s ability to change) and neurogenesis (the growth of new neurons), noting that while adult neurogenesis is limited, psychedelics may significantly enhance functional plasticity. He also discusses the entropic brain hypothesis, suggesting that increased brain entropy under psychedelics may lead to richer subjective experiences and therapeutic breakthroughs. Research shows that psilocybin therapy may reduce rigid brain network segregation, increasing global brain connectivity — correlating with symptom improvement in depression.